GAMMA Investing LLC Has $646,000 Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

GAMMA Investing LLC cut its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 36.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 907 shares of the biopharmaceutical company’s stock after selling 529 shares during the period. GAMMA Investing LLC’s holdings in Regeneron Pharmaceuticals were worth $646,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Principal Financial Group Inc. lifted its stake in Regeneron Pharmaceuticals by 1.7% in the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock valued at $181,961,000 after buying an additional 2,828 shares during the period. DGS Capital Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 13.8% in the 3rd quarter. DGS Capital Management LLC now owns 429 shares of the biopharmaceutical company’s stock valued at $451,000 after acquiring an additional 52 shares in the last quarter. Oddo BHF Asset Management Sas acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $1,598,000. American Trust bought a new position in Regeneron Pharmaceuticals during the third quarter worth $600,000. Finally, Synovus Financial Corp grew its holdings in Regeneron Pharmaceuticals by 3.4% in the third quarter. Synovus Financial Corp now owns 1,881 shares of the biopharmaceutical company’s stock worth $1,977,000 after purchasing an additional 61 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on REGN shares. Canaccord Genuity Group began coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective on the stock. Leerink Partnrs downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Bank of America reaffirmed an “underperform” rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Finally, Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $1,052.90.

Regeneron Pharmaceuticals Trading Up 0.4 %

Shares of REGN stock opened at $718.15 on Friday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The firm has a market cap of $78.92 billion, a P/E ratio of 17.77, a PEG ratio of 2.19 and a beta of 0.10. The company has a 50 day moving average of $768.44 and a 200-day moving average of $973.89. Regeneron Pharmaceuticals, Inc. has a 12-month low of $693.00 and a 12-month high of $1,211.20.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.